Detalhe da pesquisa
1.
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
PLoS Med
; 21(3): e1004360, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38502656
2.
Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.
J Infect Dis
; 212(1): 72-80, 2015 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25538277
3.
Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.
Pediatr Infect Dis J
; 38(7): 757-764, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31194712
4.
Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal.
Vaccine
; 36(43): 6424-6432, 2018 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30224199
5.
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Lancet HIV
; 5(7): e366-e378, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29898870
6.
A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.
Sci Transl Med
; 6(234): 234ra55, 2014 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24786323
7.
Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Pediatr Infect Dis J
; 31(4): e59-65, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22418661